Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the randomized COBRRA trial.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/direct-oral-anticoagulants-face-vte-trial-apixaban-confirmed-2026a10007nu?src=rss
Author :
Publish date : 2026-03-12 12:36:00
Copyright for syndicated content belongs to the linked Source.